- Poster presentation
- Open Access
Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting
© Braunstahl et al; licensee BioMed Central Ltd. 2013
- Published: 3 May 2013
- Clinical Study
- Asthma Control
- Oral Corticosteroid
Patients with severe allergic asthma (SAA) are often inadequately controlled despite available treatments including high-dose inhaled corticosteroids and long-acting β2-agonists. Use of oral corticosteroids (OCS) in SAA patients may not achieve full asthma control, and leads to significant long-term side effects. Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody approved in the European Union as an add-on therapy for patients with SAA. In clinical studies, omalizumab has been shown to reduce OCS use. Here we report the effect of omalizumab treatment on OCS maintenance use for up to 24 months in patients with SAA in the real-world eXpeRience registry.
eXpeRience was a 2-year, multicentre, non-interventional, single-arm, observational registry initiated to collect data from patients receiving omalizumab for uncontrolled SAA. Data were collected on OCS maintenance use at baseline, Month 12, and Month 24. Parameters assessed were incidence of OCS maintenance use, total daily OCS dose and change from baseline, and time to reduction in OCS dose or stopping therapy.
12 months N=734
24 months N=643
Patients on OCS maintenance monotherapy, n (%)
Mean (SD) total daily OCS dose*, mg
Mean (SD) reduction from baseline in total daily dose, mg
Patients with alteration in total OCS dose, n (%)
• no change
Mean (SD) time to either reduction or discontinuation of OCS, days
Omalizumab reduced the need for maintenance OCS use in patients with severe allergic (IgE-mediated) asthma in a real-world setting. Reduction in OCS maintenance use may reflect better asthma control and decreases the risk of long-term morbidity of corticosteroid exposure.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.